Emerging Targets in Non-Small Cell Lung Cancer

Area of Science:

• Oncology
• Genomics
• Pharmacology

Background:

• Lung cancer presents a significant global health burden.
• Targetable genomic alterations have transformed non-small cell lung cancer (NSCLC) treatment.
• Emerging molecular drivers offer new therapeutic avenues.

Purpose of the Study:

• To review emerging molecular targets in advanced NSCLC.
• To elaborate on their clinical characteristics and mechanisms.
• To summarize ongoing clinical trials and preliminary efficacy data.

Main Methods:

• Literature review of emerging molecular targets in NSCLC.
• Analysis of clinical characteristics and molecular pathways.
• Compilation of data from ongoing clinical trials.

Main Results:

• Identified KRAS non-G12C, RAF/MEK, HER3, Nectin-4, folate receptor alpha, ITGB6, and PRMT5 as key emerging targets.
• Detailed their specific mechanisms and targeted treatment availability.
• Aggregated data on clinical trial status and preliminary efficacy.

Conclusions:

• Emerging molecular targets show significant potential for advanced NSCLC.
• Ongoing clinical trials are crucial for validating these targets.
• These advancements can guide future NSCLC treatment strategies and improve patient outcomes.